内皮素A受体选择性拮抗剂PD 156707的发现与开发。

Q4 Pharmacology, Toxicology and Pharmaceutics Pharmaceutical biotechnology Pub Date : 1998-01-01 DOI:10.1007/0-306-47384-4_5

A M Doherty, A C Uprichard

{"title":"内皮素A受体选择性拮抗剂PD 156707的发现与开发。","authors":"A M Doherty, A C Uprichard","doi":"10.1007/0-306-47384-4_5","DOIUrl":null,"url":null,"abstract":"PD 156707 is a highly potent, selective antagonist of the ETA receptor that has demonstrated efficacy in a number of different disease models. The next few years will be exciting in the field of ET research as several compounds progress through clinical development. It is our hope that the efficacy that data demonstrated to date with PD 156707 will some day be translated into real hope for the patients who are waiting beyond the confines of our research laboratories.","PeriodicalId":19777,"journal":{"name":"Pharmaceutical biotechnology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"1998-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/0-306-47384-4_5","citationCount":"4","resultStr":"{\"title\":\"Discovery and development of an endothelin A receptor-selective antagonist PD 156707.\",\"authors\":\"A M Doherty, A C Uprichard\",\"doi\":\"10.1007/0-306-47384-4_5\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"PD 156707 is a highly potent, selective antagonist of the ETA receptor that has demonstrated efficacy in a number of different disease models. The next few years will be exciting in the field of ET research as several compounds progress through clinical development. It is our hope that the efficacy that data demonstrated to date with PD 156707 will some day be translated into real hope for the patients who are waiting beyond the confines of our research laboratories.\",\"PeriodicalId\":19777,\"journal\":{\"name\":\"Pharmaceutical biotechnology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1998-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1007/0-306-47384-4_5\",\"citationCount\":\"4\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmaceutical biotechnology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/0-306-47384-4_5\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Pharmacology, Toxicology and Pharmaceutics\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmaceutical biotechnology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/0-306-47384-4_5","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}

引用次数: 4

摘要

PD 156707是一种高效的选择性ETA受体拮抗剂，已在许多不同的疾病模型中显示出疗效。随着几种化合物通过临床开发取得进展，未来几年将是ET研究领域令人兴奋的一年。我们希望，PD 156707迄今为止所显示的疗效数据有朝一日能转化为真正的希望，为那些在我们研究实验室之外等待的患者带来希望。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Discovery and development of an endothelin A receptor-selective antagonist PD 156707.

PD 156707 is a highly potent, selective antagonist of the ETA receptor that has demonstrated efficacy in a number of different disease models. The next few years will be exciting in the field of ET research as several compounds progress through clinical development. It is our hope that the efficacy that data demonstrated to date with PD 156707 will some day be translated into real hope for the patients who are waiting beyond the confines of our research laboratories.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助